Actively Recruiting
Evaluating GNT0004 Gene Therapy Safety and Effectiveness in Ambulatory Boys Aged 6 to 10 with Duchenne Muscular Dystrophy Using a Randomized, Placebo-Controlled, Crossover Design with Long-Term Follow-Up
Led by Genethon · Updated on 2026-10-13
77
Participants Needed
14
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating GNT0004, a gene therapy using a recombinant adeno-associated viral vector designed to deliver a shortened but functional dystrophin gene to treat Duchenne muscular dystrophy DMD in boys. DMD is caused by mutations in the dystrophin gene, leading to muscle damage from lack of this key protein. This therapy aims to slow disease progression by producing dystrophin in heart and skeletal muscles. The study has three parts. Part 1 involved testing two doses of GNT0004 in five boys to determine the best dose with acceptable safety. Part 2 is a randomized, blinded phase lasting 18 months where participants receive either GNT0004 or a placebo after 18 months, those on placebo switch to GNT0004 and vice versa. Part 3 is a long-term follow-up lasting up to five years to monitor safety and treatment effects in all participants who received GNT0004. Participants undergo assessments including muscle biopsies, blood tests, MRI scans, and functional tests like the North Star Ambulatory Assessment, performed at various times throughout the study. Researchers monitor safety by tracking adverse events and immune responses. Long-term follow-up includes measuring muscle function and respiratory capacity over five years. The study involves ambulant boys aged 6 to 10 years with confirmed DMD who meet specific health criteria.
CONDITIONS
Brief Title
A Clinical Study to Assess Safety, Efficacy and Pharmacodynamic Profile of GNT0004 in Duchenne Muscular Dystrophy
Research Team
M
Medical Lead
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here